Emmecell Completes Final Cell Therapy Dosing In U.S. Clinical Trial For Corneal Edema

Emmetrope Ophthalmics LLC, known as Emmecell, a leader in the biotechnology sector focusing on cell-based therapies for severe eye conditions, has recently announced a significant achievement in its clinical trial for EO2002. This innovative therapy is designed to treat corneal edema, a condition that can lead to vision loss and pain. The final dose has been administered to the last participant in a U.S. trial that is both randomized and double-masked, spanning multiple centers. This marks a pivotal step in the development of EO2002, which is distinguished as a first-in-class, non-surgical cell therapy. It utilizes Emmecell’s proprietary Magnetic Cell Delivery (MCD) nanotechnology platform to potentially modify the disease course.

Corneal edema affects approximately 10% of patients severely enough that they consider corneal transplantation surgery, which comes with high risks. EO2002 presents a promising alternative that could eliminate the need for such invasive procedures. Sumit Garg, MD, Chair of the Emmecell Cornea Advisory Board and a Professor of Ophthalmology at the University of California, Irvine, expressed his enthusiasm for the project. He highlighted the significant milestone reached with the completion of dosing and the potential impact of corneal endothelial cell injections across the spectrum of corneal edema.

Emmecell anticipates topline results from its trials in the latter half of 2024, with plans for a phase 3 pivotal study set for early 2025. Noelia Kunzevitzky, PhD, COO of Emmecell, extended her gratitude towards clinical trial sites, partners, investors, and investigators for their crucial role in reaching this milestone. She underscored the collective effort of prominent U.S. hospitals and clinics in advancing towards a cure for corneal blindness globally.

In an effort to further its mission, Emmecell has partnered with Eversight, a leading global nonprofit eye bank. This collaboration aims to advance cell therapies like EO2002 and address the global challenge of curing blindness through innovative solutions.

Corneal edema occurs when the endothelial layer of cells in the cornea diminishes in number due to trauma from surgery or disease, leading to swelling and loss of optical clarity. Currently, advanced cases have no non-surgical treatment options approved, leaving corneal transplantation surgery or endothelial keratoplasty as the only solutions. These procedures are not only technically challenging but also limited by the availability of donated human eye tissue.

The MCD nanotechnology platform by Emmecell represents a revolutionary approach in regenerative medicine. It addresses key challenges in delivering, retaining, and integrating cell therapies into target tissues effectively. This technology offers a safe and effective non-surgical method for transplanting corneal endothelial cells directly into the eye.

Based in Menlo Park, California, Emmecell is at the forefront of developing cell-based therapies for eye diseases through its MCD nanotechnology platform. With a strong intellectual property portfolio focused on ophthalmic indications such as corneal edema and macular degeneration, Emmecell continues to lead innovation in this field. For more information about their groundbreaking work and future endeavors, visit emmecell.com.